Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Analyst Ratings
Hold
5 Buy
19 Hold
5 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SRPT Stock 12 Month Forecast
Average Price Target
$22.04
▲(38.53%Upside)
| Highest Price Target$80.00 | Average Price Target$22.04 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$16
Hold
0.57%
Upside
Reiterated
07/30/25
Sarepta Therapeutics' overall stock score is 54, reflecting its strong revenue growth and long-term demand potential. However, profitability issues, technical weakness, and recent corporate challenges weigh heavily on the score. The company's strategic initiatives could improve its position, but investors should be cautious of the operational and regulatory risks.
RBC Capital
$10→$14
Hold
-12.01%
Downside
Reiterated
07/31/25
Barclays
$10→$22
Hold
38.28%
Upside
Upgraded
07/30/25
Citi
$7→$12
Sell
-24.58%
Downside
Reiterated
07/30/25
Cantor Fitzgerald
$14
Hold
-12.01%
Downside
Reiterated
07/29/25
Oppenheimer
$30→$37
Buy
132.56%
Upside
Upgraded
07/29/25
William Blair
―
Hold
―
Reiterated
07/29/25
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and Roche Holding AG (Other OTC: RHHVF)We have updated our model to reflect the recent pause in ex-U.S. shipments, which we expect will lead to a decrease in contract manufacturing and royalty revenue from Roche. We now model full year 2025 revenue of $1.9 billion.
Piper Sandler
$11→$15
Hold
-5.72%
Downside
Reiterated
07/29/25
Bernstein
$13
Hold
-18.29%
Downside
Initiated
07/29/25
Morgan Stanley
$15→$20
Hold
25.71%
Upside
Reiterated
07/29/25
Mizuho Securities
$14→$19
Hold
19.42%
Upside
Reiterated
07/29/25
J.P. Morgan
$16→$24
Hold
50.85%
Upside
Upgraded
07/29/25
H.C. Wainwright
$5
Sell
-68.57%
Downside
Reiterated
07/29/25
Leerink Partners
―
Hold
―
Reiterated
07/28/25
Wells Fargo
$48
Buy
201.70%
Upside
Reiterated
07/28/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$16
Hold
0.57%
Upside
Reiterated
07/30/25
Sarepta Therapeutics' overall stock score is 54, reflecting its strong revenue growth and long-term demand potential. However, profitability issues, technical weakness, and recent corporate challenges weigh heavily on the score. The company's strategic initiatives could improve its position, but investors should be cautious of the operational and regulatory risks.
RBC Capital
$10→$14
Hold
-12.01%
Downside
Reiterated
07/31/25
Barclays
$10→$22
Hold
38.28%
Upside
Upgraded
07/30/25
Citi
$7→$12
Sell
-24.58%
Downside
Reiterated
07/30/25
Cantor Fitzgerald
$14
Hold
-12.01%
Downside
Reiterated
07/29/25
Oppenheimer
$30→$37
Buy
132.56%
Upside
Upgraded
07/29/25
William Blair
―
Hold
―
Reiterated
07/29/25
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and Roche Holding AG (Other OTC: RHHVF)We have updated our model to reflect the recent pause in ex-U.S. shipments, which we expect will lead to a decrease in contract manufacturing and royalty revenue from Roche. We now model full year 2025 revenue of $1.9 billion.
Piper Sandler
$11→$15
Hold
-5.72%
Downside
Reiterated
07/29/25
Bernstein
$13
Hold
-18.29%
Downside
Initiated
07/29/25
Morgan Stanley
$15→$20
Hold
25.71%
Upside
Reiterated
07/29/25
Mizuho Securities
$14→$19
Hold
19.42%
Upside
Reiterated
07/29/25
J.P. Morgan
$16→$24
Hold
50.85%
Upside
Upgraded
07/29/25
H.C. Wainwright
$5
Sell
-68.57%
Downside
Reiterated
07/29/25
Leerink Partners
―
Hold
―
Reiterated
07/28/25
Wells Fargo
$48
Buy
201.70%
Upside
Reiterated
07/28/25
Best Analysts Covering Sarepta Therapeutics
1 Month
xxx
Success Rate
20/33 ratings generated profit
Average Return
-0.13%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.61% of your transactions generating a profit, with an average return of -0.13% per trade.
3 Months
xxx
Success Rate
21/38 ratings generated profit
Average Return
+5.15%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.26% of your transactions generating a profit, with an average return of +5.15% per trade.
1 Year
Success Rate
19/38 ratings generated profit
Average Return
+6.13%
reiterated a buy rating 14 days ago
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +6.13% per trade.
2 Years
xxx
Success Rate
16/38 ratings generated profit
Average Return
+4.08%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 42.11% of your transactions generating a profit, with an average return of +4.08% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SRPT Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
45
47
53
49
44
Buy
15
7
8
10
10
Hold
5
10
16
33
78
Sell
5
3
1
1
11
Strong Sell
0
0
0
1
4
total
70
67
78
94
147
Each month's total comprises the sum of three months' worth of ratings.
SRPT Financial Forecast
SRPT Stock Forecast FAQ
What is SRPT’s average 12-month price target, according to analysts?
Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is 22.04.
What is SRPT’s upside potential, based on the analysts’ average price target?
Sarepta Therapeutics has 38.53% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SRPT a Buy, Sell or Hold?
Sarepta Therapeutics has a consensus rating of Hold which is based on 5 buy ratings, 19 hold ratings and 5 sell ratings.
What is Sarepta Therapeutics’s price target?
The average price target for Sarepta Therapeutics is 22.04. This is based on 29 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $5.00. The average price target represents 38.53% Increase from the current price of $15.91.
The highest analyst price target is $80.00 ,the lowest forecast is $5.00. The average price target represents 38.53% Increase from the current price of $15.91.
What do analysts say about Sarepta Therapeutics?
Sarepta Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 29 Wall Streets Analysts.
How can I buy shares of SRPT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.